

SUMMARY PAGE

EITHER PARTY MAY, WITHOUT FURTHER CONSULTATION OR PERMISSION,

RELEASE THIS SUMMARY PAGE TO THE PUBLIC.

TITLE OF CRADA: Evaluation of Avidea's synthetic, polymer-based vaccine technology, "Immunotherapeutic Nanoscaffolds" (IMNs) for infectious disease prevention and cancer treatment in animal models

PHS [IC] Component: National Institute of Allergy and Infectious Diseases ("NIAID")

IC Principal Investigator: Dr. Robert Seder

Collaborator: Avidea Technologies

Collaborator Principal Investigator: Dr. Geoffrey Lynn

TERM OF CRADA: Seven (7) years from the Effective Date.

EXPIRATION: February 23, 2024

ABSTRACT OF THE RESEARCH PLAN:

The National Institute of Allergy and Infectious Diseases (NIAID) and Avidea Technologies (Avidea) have entered into an agreement to evaluate the therapeutic potential of Avidea's polymer-based vaccine technology, "Immunotherapeutic Nanoscaffolds" (IMNs), including Star polymers and self-assembling nanoparticles based on amphiphilic polymers (SNAP), in preclinical animal models for cancer, infectious and inflammatory diseases.